Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Agios Pharmaceuticals, Inc. reported revenue of $54M, up 48.0% year over year. Operating margin was -873.9% and net margin -764.0%, on a free-cash-flow margin of -698.3% with capital expenditure at 8.0% of revenue. Every figure is computed directly from AGIO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $54M | -873.9% | -764.0% |
| FY2024 | $36M | -1166.5% | 1845.9% |
| FY2023 | $27M | -1459.5% | -1312.6% |
| FY2022 | $14M | -2732.1% | -1627.8% |
| FY2021 | $0M | n/a | n/a |
How does AGIO compare against its actual peer set?
The full CompsDesk Peer Benchmark Pack: up to 14 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, provenance for every number, board-ready PDF + CSV. One-off $249.
Related in the same sector: ABBV · ABCL · ABT · ABUS · ACAD · ACNT
See AGIO benchmarked against two sector peers (free) →
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.